Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Pulmonary Hypertension: New Potential in a Limited Market' returned 43 results - Page 1 of 3   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos   Datamonitor, March 2009, Pages: 134 limitations 129 APPENDIX B 131 Contributing experts 131 Report methodology 131 List of Tables Table 1: Clinical classifications of pulmonary arterial hypertension - Venice, 2003 15 Table 2: New York Heart Nitric Oxide - Therapeutics, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 276 failure Pulmonary hypertension NO-based treatment of pulmonary hypertension Inhaled nebulized nitrite for neonatal pulmonary hypertension Gene therapy for pulmonary hypertension Asthma iNOS inhibitors Delivering Drugs by Inhalation   Greystone Associates, Dec 2010 Landscape - Prescribing Trends and Growth Factors - Emerging Inhaled Therapies - Systemic Drug Delivery - Alpha-1 Deficiency - Bioterror - Cystic Fibrosis - Diabetes - Pulmonary Hypertension - Immune System Cardiovascular Drug Delivery - Technologies, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 264 Drug delivery in the management of pulmonary hypertension Prostacyclin by inhalation Endothelin receptor antagonist treatment of PAH Anticoagulation in cardiovascular disease Oral heparin Low European Orphan Diseases Market   Frost & Sullivan, Dec 2008, Pages: 88 thoroughly examine the following markets: orphan diseases, Gaucher’s Disease and Pulmonary Arterial Hypertension (PAH) markets in Europe. This analysis is available through our Pharmaceuticals & Biotechnology Evolving Strategies for Rare-Disease Drug Development   Decision Resources, Inc., July 2011 of repurposing a current therapy for a highly lucrative rare disease, Novartis’s novel approach of studying disease pathologies to identify new targets and develop drugs with the potential to be used in multiple Biomarkers - Technologies, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 864 stress as a biomarker of disease Role of TNF in acute coronary syndromes Biomarkers for pulmonary arterial hypertension Biomarkers of abdominal aortic aneurysm Genetic biomarkers for cardiovascular Cardiovascular Drug Discoveries 2008   Espicom Business Intelligence Ltd, April 2008, Pages: 314 limited, particularly for patients with more severe PAH. There are, however, a number of new and potential entrants into this market: Thelin (sitaxsentan), an endothelin receptor antagonist which has been Cell Therapy - Technologies, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 1008 crest stem cells from adult hair follicles Transdifferentiation potential of adult stem cells Limitations of adult stem cells Comparison of human stem cells according to derivation VENT cells Stem Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, Q4 2010   Global Markets Direct, Dec 2010, Pages: 134 , 2010: Clinical Data Receives Orphan Drug Designation For PRX-8066 For Pulmonary Arterial Hypertension Oct 29, 2010: Almirall And Forest Report Preliminary Topline Phase III Study Results Of Aclidinium Electrocardiography (ECG) Devices - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015   Axis Research Mind, Feb 2011, Pages: 332 MEDICARE’S COVERAGE FOR HYPERTENSION WITH BIOZ(R) ICG TECHNOLOGY A NEW STANDARD IN CARDIAC SPECT RECONSTRUCTION A REVOLUTIONIZED ELECTROPHYSIOLOGY (EP) FOR CARDIAC LIDCO PRODUCTS ACCEPTED IN SOUTH KOREA Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies   GBI Research, Feb 2011, Pages: 209 .5.1 Hypertension 104 6.5.2 Dyslipidemia 109 6.5.3 Pulmonary Arterial Hypertension (PAH) 114 6.5.4 Myocardial Infarction 119 6.6 Oncology 124 6.6.1 Bladder Cancer 124 6.6.2 Lung Cancer 129 6.6.3 Non-Small Cell Lung GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing   GBI Research, Nov 2011, Pages: 143 about 30% of the 800 odd GPCRs have been targeted so far by currently marketed medicines leads to the conclusion that GPCR research has immense potential to bring out new therapies. Basic Telemonitoring: Challenges & Opportunities   Espicom Business Intelligence Ltd, Nov 2011, Pages: 152 providers to find new, cost-effective ways to manage their patients and reduce the burden of potentially preventable diseases – two areas where telemonitoring can help considerably. The key focus Telemedicine Market in Brazil, Russia, India, China (BRIC)   Markets and Markets, June 2010, Pages: 194 due to increase in the number of patients suffering from chronic diseases such as chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF), asthma, hypertension, and diabetes Cardiac Prosthetic Devices - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015   Axis Research Mind, Feb 2011, Pages: 331 ’S NEW CARDIAC TREATMENT THE ONLY SYNCHRONIZED SURGICAL AND CATHETER BASED ATRIAL FIBRILLATION CARDIAC SCIENCE CORPORATION WITH CARDIAC DISEASES HEALING METHOD LOCAL MEDICARE’S COVERAGE FOR HYPERTENSION Cardiac Defibrillators - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015   Axis Research Mind, Feb 2011, Pages: 360 ’S NEW CARDIAC TREATMENT THE ONLY SYNCHRONIZED SURGICAL AND CATHETER BASED ATRIAL FIBRILLATION CARDIAC SCIENCE CORPORATION WITH CARDIAC DISEASES HEALING METHOD LOCAL MEDICARE’S COVERAGE FOR HYPERTENSION Cardiac Pacemakers - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015   Axis Research Mind, Feb 2011, Pages: 333 ’S NEW CARDIAC TREATMENT THE ONLY SYNCHRONIZED SURGICAL AND CATHETER BASED ATRIAL FIBRILLATION CARDIAC SCIENCE CORPORATION WITH CARDIAC DISEASES HEALING METHOD LOCAL MEDICARE’S COVERAGE FOR HYPERTENSION Cardiac Catheters - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015   Axis Research Mind, Feb 2011, Pages: 332 ’S NEW CARDIAC TREATMENT THE ONLY SYNCHRONIZED SURGICAL AND CATHETER BASED ATRIAL FIBRILLATION CARDIAC SCIENCE CORPORATION WITH CARDIAC DISEASES HEALING METHOD LOCAL MEDICARE’S COVERAGE FOR HYPERTENSION Inferior Vena Cava (IVC) Filters - Emerging Markets (Brazil, Russia, India, China, South Africa And South Korea), 2009-2015   Axis Research Mind, Feb 2011, Pages: 333 MEDICARE’S COVERAGE FOR HYPERTENSION WITH BIOZ(R) ICG TECHNOLOGY A NEW STANDARD IN CARDIAC SPECT RECONSTRUCTION A REVOLUTIONIZED ELECTROPHYSIOLOGY (EP) FOR CARDIAC LIDCO PRODUCTS ACCEPTED IN SOUTH KOREA Results:  First -   Prev -   1 -   2 -   3 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network